Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
13.10
+0.92 (7.55%)
Jul 23, 2025, 10:39 AM - Market open
Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma.
The company is headquartered in Frederick, Maryland.
Cartesian Therapeutics, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 22, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Carsten Brunn |
Contact Details
Address: 7495 New Horizon Way Frederick, Maryland 21703 United States | |
| Phone | 301 348 8698 |
| Website | cartesiantherapeutics.com |
Stock Details
| Ticker Symbol | RNAC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453687 |
| CUSIP Number | 816212302 |
| ISIN Number | US8162123025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carsten Brunn Ph.D. | President, Chief Executive Officer and Director |
| Blaine T. Davis | Chief Financial Officer |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer |
| Dr. Metin Kurtoglu M.D., Ph.D. | Consultant |
| Dr. Emily English Ph.D. | Chief Operating Officer |
| Matthew Bartholomae J.D. | General Counsel and Secretary |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 8, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 8, 2025 | 8-K | Current Report |